scholarly journals Preoperative Cognitive Intervention Reduces Cognitive Dysfunction in Elderly Patients after Gastrointestinal Surgery: A Randomized Controlled Trial

2015 ◽  
Vol 21 ◽  
pp. 798-805 ◽  
Author(s):  
Wen Ouyang
2014 ◽  
Vol 4 (1) ◽  
pp. 6 ◽  
Author(s):  
Minhthy Meineke ◽  
Richard L Applegate ◽  
Thomas Rasmussen ◽  
Donald Anderson ◽  
Sherif Azer ◽  
...  

2020 ◽  
Author(s):  
Xia Liu ◽  
Peng Zhang ◽  
MengXue Liu ◽  
JunLi Ma ◽  
XinChuan Wei ◽  
...  

Abstract Background: At present it remains uncertain as to whether carbohydrate (200 ml) loaded 2 hours before anesthesia induction combined with intraoperative goal-directed fluid therapy (GDFT) is beneficial to elderly patients undergoing gastrointestinal operations. As such, a randomized controlled trial was designed to evaluate the relative impact of perioperative fluid optimisation versus conventional fluid therapy (CFT) on clinical outcomes in elderly patients following gastrointestinal surgery.Methods: A total of 120 elderly patients undergoing gastrointestinal surgery were randomized into a CFT group (n = 60) with traditional methods of fasting and water-deprivation, and a GDFT group (n = 60) with carbohydrate (200 ml) load 2 hours before anesthesia induction. The CFT group underwent routine monitoring during surgery, however, the GDFT group was conducted by a Vigileo/FloTrac monitor with cardiac index (CI), stroke volume variation (SVV), and mean arterial pressure (MAP). For all patients, demographic information, intraoperative parameters and postoperative outcomes were recorded.Results: Patients in the GDFT group were administered less crystalloid fluid (1111 ± 442.9 ml vs 1411 ± 412.6 ml; p = 0.000) and produced less urine output (200 ml [150-300] vs 400 ml [290-500]; p = 0.000) relative to patients in the CFT group. Moreover, GDFT was associated with a shorter average time to first flatus (55 ± 13.9 hours vs 65 ± 22.6 hours; p = 0.004) and oral intake (72 ± 17.4 hours vs 85 ± 27.5 hours; p = 0.002), as well as a reduction in the rate of postoperative complications (14 (25.5%) vs 27(47.4%) patients; p = 0.016). However, postoperative hospitalization or hospitalization expenses were similar between groups.Conclusions: Focused on elderly patients undergoing open gastrointestinal surgery, we found perioperative fluid optimisation may be associated with improvement of bowel function and a lower incidence of postoperative complications. Trial registration: ChiCTR, ChiCTR1800018227. Registered 6 September 2018 - Retrospectively registered, http://www.chictr.org.cn/showproj.aspx?proj=29899


Author(s):  
Susan J. Pressler ◽  
Miyeon Jung ◽  
Irmina Gradus-Pizlo ◽  
Marita Titler ◽  
Dean Smith ◽  
...  

2021 ◽  
Vol 8 (1) ◽  
pp. 35
Author(s):  
Annie C. Lajoie ◽  
Annie-Louise Lafontaine ◽  
Gabriel Leonard ◽  
R. John Kimoff ◽  
Andrea Benedetti ◽  
...  

<p class="abstract"><strong>Background:</strong> Parkinson’s disease (PD) is the second most frequent neurodegenerative disease and is associated with cognitive dysfunction. Obstructive sleep apnea (OSA) has been linked with cognitive dysfunction in the general population and in PD. Treatment with positive airway pressure (PAP), can improve cognition in the general population and in patients with other neurodegenerative diseases. However, the effect of PAP therapy on cognitive function has not been well studied in PD.</p><p class="abstract"><strong>Methods:</strong> This randomized controlled trial will assess the effect of 6 months of PAP therapy versus placebo on global cognitive function in PD patients with OSA and reduced baseline cognition. Secondary outcomes will include quality of life and other non-motor symptoms of PD. Exploratory outcomes will be specific domains of neurocognitive function and symptoms of REM sleep behaviour disorder.</p><p class="abstract"><strong>Conclusions: </strong>PD-related cognitive dysfunction often evolves towards dementia and has substantial personal, social and healthcare costs. Few interventions have been shown to improve cognition in PD to date. If positive, results from our study could prove OSA to be a new therapeutic target relevant to cognition and would support more systematic screening for OSA in PD patients with cognitive decline.</p><p class="abstract"><strong>Trial Registration:</strong> Trial registration number is NCT02209363.</p>


Sign in / Sign up

Export Citation Format

Share Document